|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
1960s
|
|
gptkbp:ATCCode
|
gptkb:N03AF01
|
|
gptkbp:CASNumber
|
298-46-4
|
|
gptkbp:chemicalFormula
|
C15H12N2O
|
|
gptkbp:contraindication
|
history of bone marrow depression
hypersensitivity to carbamazepine
|
|
gptkbp:discoveredBy
|
gptkb:Geigy
|
|
gptkbp:drugClass
|
gptkb:mood_stabilizer
gptkb:anticonvulsant
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
oral suspension
chewable tablet
|
|
gptkbp:genericName
|
gptkb:carbamazepine
|
|
gptkbp:interactsWith
|
gptkb:milk
gptkb:phenytoin
gptkb:warfarin
gptkb:erythromycin
oral contraceptives
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:KEGGID
|
D00294
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
|
|
gptkbp:MedlinePlusID
|
a682237
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyRisk
|
teratogenic
|
|
gptkbp:PubChem_CID
|
3213
2554
CHEMBL417
DB00564
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
rash
drowsiness
hyponatremia
|
|
gptkbp:UNII
|
33CM23913M
|
|
gptkbp:usedFor
|
gptkb:trigeminal_neuralgia
bipolar disorder
epilepsy
|
|
gptkbp:bfsParent
|
gptkb:Ciba-Geigy
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tegretol
|